TrialBlood advances2023

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.

Benjamin A Derman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.